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Background: The rise of genomic studies in Africa – not least due to projects funded under H3Africa – is
associated with the development of a small number of biorepositories across Africa. For the ultimate success of
these biorepositories, the creation of cell lines including those from selected H3Africa samples would be beneficial.
In this paper, we map ethical challenges in the creation of cell lines.
Discussion: The first challenge we identified relates to the moral status of cells living in culture. There is no doubt
that cells in culture are alive, and the question is how this characteristic is relevant to ethical decision-making. The
second challenge relates to the fact that cells in culture are a source of cell products and mitochondrial DNA. In
combination with other technologies, cells in culture could also be used to grow human tissue. Whilst on the one
hand, this feature increases the potential utility of the sample and promotes science, on the other it also enables
further scientific work that may not have been specifically consented to or approved. The third challenge relates to
ownership over samples, particularly in cases where cell lines are created by a biobank, and in a different country
than where samples were collected. Relevant questions here concern the export of samples, approval of secondary
use and the acceptability of commercialisation. A fourth challenge relates to perceptions of blood and bodily integrity,
which may be particularly relevant for African research participants from certain cultures or backgrounds. Finally, we
discuss challenges around informed consent and ethical review.
Summary: In this paper, we sought to map the myriad of ethical challenges that need to be considered prior to
making cell line creation a reality in the H3Africa project. Considering the relative novelty of this practice in Africa,
such challenges will need to be considered, discussed and potentially be resolved before cell line creation in Africa
becomes financially feasible and sustainable. We suggest that discussions need to be undertaken between
stakeholders internationally, considering the international character of the H3Africa project. We also map out
avenues for empirical research.
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Genomic research in Africa has received significant sup-
port under a funding programme called ‘H3Africa’, where
H3 stands for Humans, Heredity and Health. H3Africa
(www.h3africa.org) is a joint funding initiative by the
Wellcome Trust in the United Kingdom and the National* Correspondence: Jantina.devries@uct.ac.za
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with support from the African Society of Human Genetics.
H3Africa supports individual research projects, a bio-
informatics network (H3A BioNet) and a small number of
African biorepositories to store (aliquots of) samples.a
Central to the establishment of biorepositories on the
African continent (and elsewhere) is the creation of cell
lines as a value-added service. A cell line is made by tak-
ing a human body cell such as a blood cell or skin cell
and changing some of its’ genetics in order to make thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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established, the cells in the cell line will keep on repro-
ducing in a flask as long as they are taken care of – in
other words, as long as they are fed and refreshed, and
have oxygen to breathe. Because the cells in culture ori-
ginate from a single cell, they are genetically uniform
and share the genetic makeup of the person from whom
the cell was obtained.
At the most basic level, the immortalisation of cells is
considered as the optimal way to preserve DNA outside
the human body. Once cell lines are created, they form
an inexhaustible resource for DNA and, of course, other
cell products too. A second advantage to the creation of
cell lines, therefore, lies in that they may enable func-
tional genomic work to be conducted. Whereas a sample
collected at one moment in time may allow for only very
limited functional work (e.g. RNA expression studies), a
cell line allows researchers to study cellular responses to
different stimuli that emulate infection or disease. In this
way, it allows researchers to identify not only genetic
factors involved in disease causation or prevention, but
also to study the actual effect of those factors. A third
advantage is that the collection of new samples is not
necessary and thus may minimise the burden and cost
of patient recruitment. The preservation of cells in cul-
ture allows for the application of the latest scientific
techniques on these samples. An example of such a
technology in development is single-cell genomics, which
allows for detailed genomic and transcriptomic studies on
the basis of a single cell [1,2].
However, the creation of cell lines also raises ethical is-
sues, not all of which are thoroughly understood. In the
African context, the creation of cell lines is relatively
novel. In this paper, we will map the ethical issues
around the creation of cell lines and discuss those that
need to be addressed before the development of African
sample repositories, as discussed by the H3Africa Work-
ing Group on Ethics.
The historical creation of cell lines from African samples
The creation of cell lines became technologically feasible
in the 1950s, when the first cell line that multiplied in vitro
was generated using the cells of a cancer patient called
Henrietta Lacks, also known as HeLa [3]. Since then, cell
biology has found other ways of generating cell lines, in-
cluding the reprogramming of adult body cells into stem
cells [4,5]. Induced Pluripotent Stem Cell (IPSC) technol-
ogy allows for body cells to be transformed into stem cells
which can be induced to develop into cells of specialised
body tissues, for instance neurones or fat cells through a
few intermediary steps. Theoretically, cells derived from
cell lines could also be used for these purposes. This tech-
nology raises important ethical issues that need to be con-
sidered in the context of cell line immortalisation.Researchers have created cell lines from human speci-
mens for over five decades, and have also used this tech-
nology to create cell lines from African samples – many
of which are currently preserved by the Coriell Institute
in the USA. Specific examples are cell lines created for
the Biaka pygmy population from the Central African
Republic and the Mbuti pygmy population from the
Democratic Republic of Congo.b Many of the earlier
samples were not collected purposively for the creation
of cell lines. More recent research, however, has wit-
nessed the collection of African human samples specific-
ally for cell line creation. This is the case for the 90
HapMap cell lines derived from samples obtained from
Yoruba people living in Ibadan, Nigeria [6], and for the
samples included in the 1000 Genomes study [7]. The lat-
ter has generated cell lines for Luhya people from Kenya,
Mende people from Sierra Leone and Esan people from
Nigeria. Cell lines are also available for samples col-
lected for 100 people from The Gambia with undisclosed
ethnicity.c Many more cell lines may have been devel-
oped from samples obtained from African people, but
these collections are thought to be scattered across
laboratories and universities across the globe, and no
comprehensive record exists. In the context of H3Africa
studies, the expectation is that it would ultimately be
beneficial to create cell lines for (selected) samples so
that samples will not be limited for future research and
additional resources will not be needed for renewed sam-
ple collection but this is not currently economically and
technologically feasible.
Discussion
Are cell lines really different?
A key question relevant to a discussion of the ethical is-
sues relating to the creation of cell lines is whether this
practice distinguishes itself from other forms of sample
manipulation in a way that is morally relevant. In other
words, are there aspects of the creation of cell lines that
raise ethical concerns in and of themselves?
On one extreme, the creation of cell lines could be
considered as a way of preserving genetic material, and
of ensuring access to this material in the future. Propo-
nents of this view argue that the technique minimises
harm to participants by reducing the need for additional
samples, whilst maximising benefit by enabling the de-
velopment of a more comprehensive picture of disease,
which will ultimately be of benefit to patients. From this
perspective, the creation of cell lines is not morally dif-
ferent from the collection of a finite genetic sample.
An opposing view could be that cells in culture are
living: they breathe oxygen, consume nutrients, multiply
and can die. If they have the ability to die, then they logic-
ally need to be considered alive as well. This is significantly
different from other genomic material collection which
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considered in this way, the creation of cell lines touches on
concepts that were previously associated with, for example,
deities or superheroes – immortality and the ability to live
and multiply outside of the body.
The latter observation – that cells in culture are alive –
may be morally significant. Obviously, cell lines in a flask
are not experiencing life in the same way that a living hu-
man does, and they should therefore not be treated the
same as the conscious, living persons. They share with the
humans from whom they came, all of the genetic material
as well as the ability to live in vitro under artificially engi-
neered circumstances. They have the ability to provide in-
formation on the physiological body of the person who
donated them, but do not seem to have the same ability to
provide information on the other aspects that make up a
person – for instance, their emotional state, thoughts and
lived experiences. That cells outside of the body do have
meaning may be clear from a comparison with cells in
semen [8]. However, to what degree these samples still
‘pertain to’ the person, or whether the sample donors re-
tain ‘interests in’ the cell lines, is not currently clear and
needs further discussion and investigation [9]. A complicat-
ing factor is that (collections of) cell lines may be used to
provide information not only on the person, but on the
population group that they form part of – a fear that is
prevalent in the context of genomic research [10].
Cells in culture: a source of cell products
A second way in which cell lines are different from finite
genomic samples is that they offer a source of cell prod-
ucts other than just nuclear DNA. Cell lines offer access
not only to mitochondrial DNA, but also to transcrip-
tion RNA, expressed proteins and other cell products.
This is morally relevant most importantly because it sig-
nificantly increases the usefulness of the donated sample.
For instance, rather than just examining the ‘genetic
blueprint’, which is static, cell lines could be used to
study (genetic) responses to environmental stimuli, in-
cluding infection with disease-causing pathogens or
therapeutic drugs. This means that rather than just fo-
cusing on an individuals’ genetic makeup and analysing
the influence of genetic variants on disease, the cre-
ation of cell lines allows a researcher to study disease
responses at the cellular level over time, without ne-
cessarily returning to the research participant for fur-
ther samples or information, and without having to
subject them to potentially harmful experiments. The
expectation is that using cell lines will enable re-
searchers to discover more about disease in a shorter
timeframe – which would ultimately be beneficial for
patients. Where projects focus on diseases prevalent in
Africa, the expectation would be that the benefits from
knowledge gained would accrue to African patients andthe wider population, but it may be important to in-
clude this as a specific requirement in access decisions.
If this expectation is true, then the creation of cell lines
would have moral significance in ultimately promoting
the wellbeing of African patients.
Access to mitochondrial DNA may also be relevant for
consent as it provides information about group origin,
but this may not specifically have been highlighted in
the consent forms. A concern could be that genetic ac-
counts of ancestry may be in conflict with traditional
narratives – which was apparently the case for the
Havasupai in the United States [11,12]. In that project,
genetic material collected for diabetes-related studies
from a group of Native Americans called the Havasupai
was used to study the group’s origin. This was found to
be offensive to the Havasupai and resulted in the destruc-
tion of all genetic samples held in storage. However, stud-
ies of ancestry do not need to include mitochondrial
DNA, but could equally well be done on genomic mater-
ial from the nucleus. Y-chromosomal material – which
has the same potential as mitochondrial DNA to inform
on ancestry – is routinely genotyped or sequenced in
genomic studies and this has not raised significant
concern to date. This aspect, therefore, is not unique to cell
lines; there are similar challenges for research where only a
finite DNA sample is collected.
Using cells to grow other tissues
Cells grown in culture can also be used to grow other
tissues, which is not possible if a finite sample is not
converted to cell lines. Using novel techniques such as
those developed for the creation IPSCs [4,5], researchers
in the field of regenerative medicine could theoretically
induce the cells in culture to transform into stem cells,
and then subsequently get these to develop into cells of
a different type. In other words, using IPSC techniques,
researchers could theoretically manipulate white blood
cells grown in culture to transform into muscular or
neurological cells, for instance. This would be highly ad-
vantageous for science: for example, in a study of cardio-
vascular disease, one could grow cardiomuscular cells
with the same genetic makeup as the cells of the patients
recruited into the study. This could allow researchers to
develop a much better understanding of disease pro-
cesses, without having to go through complicated and
sometimes painful procedures to extract patient-specific
tissues from their bodies. What this means is that cell
lines take on value and possibilities for application that
may transcend the value and use of the original human
body or person [13].
The use of these technologies generates a number
of ethical concerns. One challenge relates to informed
consent – whether the patient indeed agreed to allowing
such manipulations to happen on the samples. Another
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methods, for instance to support the creation of artifi-
cial gametes. Although this is currently illegal in most
jurisdictions across the world, it is difficult to monitor
how researchers use samples in the privacy of their
laboratories.
Ownership over cell lines
In the context of the H3Africa programme, the aim is to
create biorepositories across a number of countries in
Africa. The vision is that samples are shipped regionally,
and that cell lines are created, maintained and distrib-
uted from these regional African centres to researchers
elsewhere in the world. These biorepositories would be
within African institutions and access decisions would
be made by an oversight committee that is primarily
composed of people residing in Africa. The intention to
create African biorepositories seems to be a partial re-
sponse to concerns about sample export and exploit-
ation which have been raised in the context of genomic
research [14-16]. The creation of regional African re-
positories, however, does not eliminate the need for
sample export and concerns relating to ownership and
sovereignty may be as relevant when samples are shipped
from one African country to another, as when they are
shipped outside of the continent. The creation of cell
lines falls into these controversies. Both the initial sample
collector and their institution may retain interests in or
claims of ownership of samples, and collaborators may
specify ownership in material transfer agreements for
instance. However, the creation and maintenance of
cell lines requires significant financial and personnel re-
sources, and these are normally provided by the facility
that generated the cell lines. Additionally, in order for the
biorepositories to be sustainable, samples and cell lines
will likely need to be distributed at a cost. Lastly, some
particularly valuable cell lines could be patented – as
happened in the case of the HeLa cells, for instance [3].
But generating commercial gain from biological materials
is widely recognized to be problematic [9,17-19] – not
least because it may be thought to be immoral or illegal
to sell and buy body parts and because body parts may
be vested with symbolic meaning that ought not be com-
modified [20,21].
Perceptions of blood and bodily integrity
An additional challenge in the African context relates
to traditional perceptions of blood and the body. It
is well-documented that blood carries symbolic value
for many Africans [22-26]. Blood has been associated with
strength, superstition, exploitative relations, colonialism
and witchcraft, amongst others. For this reason, authors
highlight the need to carefully explain the purposes
of blood collection in the consent process and duringresearch [27,28]. Similarly, other bodily tissues such as
organs for transplantation [18], semen for artificial insem-
ination [8], and frozen research samples [13] have also
been demonstrated to carry with them aspects of the iden-
tity of the donor. An example from Cameroon is the trad-
itional practice that the placenta, or at least a part of it,
needs to be buried in the village of origin of the father,
even when the family no longer lives there. Whether the
same will apply to cell lines, samples collected for routine
medical procedures or tissues removed during operations,
remains to be investigated in the African context. Another
avenue for investigation is whether traditional African per-
ceptions on the afterlife and the spirit world could provide
opportunities to discuss ethical issues relating to cell line
creation and immortality.
Consent
The way in which these challenges have traditionally been
dealt with is by investing considerable effort in optimising
the consent procedure. One of the primary challenges in
the creation of cell lines relates to obtaining informed con-
sent for the procedure. Consent for medical research
across Africa often remains focused around specific re-
search questions, with samples obtained for use in a par-
ticular disease-based project. All of the H3Africa projects,
for instance, are disease-based meaning that enrolment
and therefore consent is primarily focused on the disease
in question. In those cases, sample and data sharing are
often of secondary importance. This is significantly differ-
ent from HapMap and 1000Genomes, where recruitment
specifically focused on the creation of cell lines. A decision
that needs to be made in the context of H3Africa studies,
therefore, is whether consent for the creation of cell lines
should be integrated in the main consent form or whether
specific consent for cell line creation should be obtained.
Greater scrutiny of the HapMap and 1000Genomes expe-
riences may also be required for guidance.
It is clear that against the foregoing discussions, there
are many challenges in obtaining informed consent for
genomic studies in Africa [28-33]. One pertinent feature
of many research contexts in Africa is the complemen-
tarity of community and individual values. Community
engagement is often a necessary step preceding individ-
ual informed consent procedures. In the case of cell line
creation, this translates into a requirement to consider
how community views can be integrated in sample gov-
ernance. In light of these concerns, it is therefore un-
likely that interactions around informed consent alone
can resolve ethical dilemmas around sample sharing and
cell line creation. Rather, we need to think creatively to
ensure that downstream decisions about the use of cell
lines created in H3Africa research, appropriately take
into consideration participant interests and are not harm-
ful. For instance, careful development of sample sharing
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forms of secondary use, are essential accompaniments to
informed consent, and have a role to play in protecting
participants’ interests.
Ethics approval and sample access
Cell line creation raises issues that are novel for ethics
committees in two ways: first, in terms of the practice it-
self, and second, in terms of the opportunity if offers for
sample re-use. For ethics committees across the contin-
ent, the usual practice is to approve the use of samples
for specific research projects. Any subsequent uses of
those samples need separate approval from that same
ethics committee. In the context of H3Africa projects,
the proposal is that ethics committees will approve the
submission of samples to the biobank, but what remains
unresolved is whether those committees will permit an-
other body (such as a sample access committee or an
ethics committee associated with the biobank) to make
decisions about appropriate secondary uses of samples.
It is important to recognise that many participant
communities across Africa are considered ‘vulnerable’
to exploitation: poor, with low research literacy and
obstructed access to healthcare. In our experience, ethics
committees in Africa recognise these contextual issues
and take their role in protecting the interests of partici-
pants very seriously. Similarly, some ethics committees in
Africa have observed that medical research in Africa has
yielded little benefit for African patients, institutions and
countries, and are becoming increasingly critical about
sample sharing and export [15]. Exactly how these con-
cerns will relate to the proposal for wide sample sharing
(through cell line creation) remains to be investigated
and experienced. What does seem clear, however, is that
the large scale creation of cell lines in the context of
H3Africa needs to be paired with a clear commitment to
building research capacity in Africa. Biobanks can also
have an ethics committee that adjudicates over ethical is-
sues such as proposals wishing to create cell lines. In
some scenarios once a biobank has been granted ethical
clearance as a bona fide biobank then an ethics commit-
tee could cede further decisions specific to the highly
specialised field of biobanking to the biobanking ethics
review committee.
Summary and recommendations
The creation of cell lines in central biobanks in Africa
raises a number of ethical challenges relating to consent,
community engagement, ownership and commercial-
isation and harmonisation of ethics review across the
continent. The absence of good regulatory guidance re-
garding biobanking and its technologies on the continent
of Africa raises many additional concerns that also need
addressing. Although in this paper, we have presentedthe various ethical challenges raised by the creation of
cell lines as disconnected, they share considerable over-
lap. For instance, the absence of a good awareness of par-
ticipants’ understanding of and perspectives on cell line
creation raises challenges for ethics review – most evi-
dently in the way ethics committees in African countries
seek to prevent exploitation through control over sec-
ondary use decisions. Also, the historical exploitation of
African people in medical research creates suspicions
around blood collection and resistance to sample export.
These issues, therefore, need to be understood together
rather than in isolation.
There is a considerable gap in knowledge about the
perspectives of African research participants on the cre-
ation of cell lines for research and therefore an urgent
need to conduct empirical studies to investigate these.
Such studies could be conducted in the context of
current H3Africa initiatives but also, for instance, could
involve members of populations for which cell lines are
already commercially available. We identify a number of
areas that need further work before the large-scale cre-
ation of cell lines from human samples could become a
reality in Africa. Most importantly what is needed is a
comprehensive understanding of the views of stake-
holders across the continent on these issues. Empirical
research needs to focus on (potential) research partici-
pants from diverse populations, in rural and urban set-
tings and from different socio-economic backgrounds. It
also needs to encapsulate researchers, medical profes-
sionals, ethics committee members and policy makers.
Such work needs to span a number of academic disci-
plines in the social sciences and humanities.
Second, it is necessary to clarify the implications of
the current legal frameworks in African countries, or de-
velop these where they are not existent or appropriate.
This would involve legal scholars on the continent, as
well as policy makers, civil society organisations and
others. Furthermore, the role of appropriate governance
mechanisms in ensuring that the creation of cell lines is
done ethically in a way that builds trust in the research
enterprise, needs to be explored. What is clear is that
such governance mechanisms must ensure that cell lines
are created for and used to promote the wellbeing of pa-
tients on the African continent.
Thirdly, attention needs to be given to developing a
governing structure that enables scientific research
whilst also protecting participant interests. Such a gov-
erning structure may require the ongoing involvement of
ethics committee members and researchers from across
the continent, particularly with regard to access and re-
use decisions. In particular, the governance structure
should consider how and whether research is likely to
benefit African patients and accommodate limitations
to informed consent. One suggestion could be that the
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Oath’ for scientists [34].
In the context of H3Africa, the development of a pol-
icy framework to guide the sharing of research samples
in biobanks is in its final stages. Also, the Consortium
has initiated a process of engagement with members of
ethics committees from across the continent to under-
stand the key ethical challenges relating to the sharing of
data and samples for genomics research in Africa. From
these processes, it is clear that the development of an
appropriate consent model to allow for the sharing of
samples and the creation of cell lines is a first priority. It
is also clear that these activities need to be embedded in
robust and thorough community engagement activities,
but questions about how community engagement can
meaningfully support the creation and redistribution of
cell lines require urgent attention. Within H3Africa,
some work is taking place to address these issues both
through empirical work and through a process of engage-
ment of stakeholders across the continent.
Endnotes
aSee http://h3africa.org/about/white-paper (accessed 12
January 2014).
bSee http://ccr.coriell.org/Sections/BrowseCatalog/
Populations.aspx?PgId=4 (accessed 13 January 2013).
cSee http://www.1000genomes.org/about (accessed 13
January 2014).
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